Provided by Tiger Trade Technology Pte. Ltd.

Soligenix, Inc.

0.4010
+0.02095.50%
Post-market: 0.42000.0190+4.74%19:47 EDT
Volume:989.16K
Turnover:408.16K
Market Cap:8.73M
PE:-0.31
High:0.4219
Open:0.3800
Low:0.3800
Close:0.3801
52wk High:3.44
52wk Low:0.2800
Shares:21.77M
Float Shares:20.77M
Volume Ratio:6.33
T/O Rate:4.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2743
EPS(LYR):-2.1354
ROE:-241.65%
ROA:-84.87%
PB:1.31
PE(LYR):-0.19

Loading ...

Soligenix Q1 EPS $(0.28), Inline

Benzinga Earnings
·
May 08

Soligenix Q1 Net Income USD -2.8 Million

THOMSON REUTERS
·
May 08

Soligenix Inc: Had No Revenue or Related Costs for Qtr Ended March 31, 2026 and 2025, Respectively

THOMSON REUTERS
·
May 08

Press Release: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Dow Jones
·
May 08

Soligenix Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
May 05

Soligenix halts Phase 3 FLASH2 HyBryte trial in CTCL for futility

Reuters
·
Apr 28

Soligenix Inc - Phase 3 Flash2 Trial of Hybryte in Ctcl Recommended to Halt for Futility

THOMSON REUTERS
·
Apr 28

Soligenix Announces Interim Results From the Phase 3 Flash2 Trial Evaluating Hybryte™ in Treatment of Cutaneous T-Cell Lymphoma

THOMSON REUTERS
·
Apr 28

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM

Reuters
·
Apr 28

Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

TIPRANKS
·
Apr 22

Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

TIPRANKS
·
Apr 21

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

TIPRANKS
·
Apr 18

Soligenix publishes corporate presentation highlighting late-stage rare disease drug pipeline

Reuters
·
Apr 09

Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy

TIPRANKS
·
Apr 03

Soligenix says HyBryte beats Valchlor in small cutaneous T-cell lymphoma study

Reuters
·
Apr 02

Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

TIPRANKS
·
Apr 02

Soligenix Q4 EPS $(0.29) Beats $(0.56) Estimate

Benzinga Earnings
·
Apr 01

Soligenix Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 01

Soligenix FY25 net loss widens 34% to $11.1 million; revenue drops to no revenue

Reuters
·
Apr 01

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Mar 31